Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972763 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
A Phase 1 study of Recalcitrant Wet Age-related Macular Degeneration, sponsored by Northern California Retina Vitreous Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01972763 is a Phase 1 study of Recalcitrant Wet Age-related Macular Degeneration that has completed, run by Northern California Retina Vitreous Associates. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01972763, a Phase 1 study of Recalcitrant Wet Age-related Macular Degeneration, has completed, sponsored by Northern California Retina Vitreous Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the study aims to see if Ranibizumab may have a greater treatment effect.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
California
- Northern California Retina Vitreous Associates - Mountain View
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01972763
The ClinicalTrials.gov registry entry for NCT01972763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northern California Retina Vitreous Associates, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recalcitrant Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01972763 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01972763 about?
NCT01972763 is a clinical study titled "Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.". The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the ...
What is the current status of trial NCT01972763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-10. Estimated completion is 2018-07.
What conditions does trial NCT01972763 study?
This clinical trial studies the following conditions: Recalcitrant Wet Age-related Macular Degeneration.
What interventions are being tested in trial NCT01972763?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01972763?
This trial is sponsored by Northern California Retina Vitreous Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01972763 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.